Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

NCT03606369 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

560

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasm
Antineoplastic Agents
Antiemetics
Quality of Life

Interventions

DRUG: Palonosetron
DRUG: Ondansetron

Sponsor

Instituto Nacional de Cancerologia de Mexico